BioMarin Pharmaceutical Inc.

Equities

BMRN

US09061G1013

Pharmaceuticals

Market Closed - Nasdaq 04:00:00 2024-03-27 pm EDT 5-day change 1st Jan Change
88.61 USD +0.99% Intraday chart for BioMarin Pharmaceutical Inc. +4.54% -8.10%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Transcript : BioMarin Pharmaceutical Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-12-2024 01:35 PM
BioMarin Pharmaceutical Says Voxzogo Leads to Height Gains in Children With Achondroplasia MT
Transcript : BioMarin Pharmaceutical Inc. Presents at Leerink Partners Global Biopharma Conference 2024, Mar-11-2024 10:40 AM
Biomarin Pharmaceutical Insider Sold Shares Worth $348,280, According to a Recent SEC Filing MT
BioMarin Pharmaceutical Appoints Cristin Hubbard as Chief Commercial Officer MT
Biomarin Announces Board Changes, Effective May 20, 2024 CI
Transcript : BioMarin Pharmaceutical Inc. Presents at TD Cowen 44th Annual Health Care Conference 2024, Mar-05-2024 12:50 PM
BioMarin Pharmaceutical Gets DOJ Subpoena for Documents Related to Vimizim, Naglazyme -- Update DJ
BioMarin Pharma gets DOJ subpoena on sponsored testing programs for two therapies RE
BioMarin Pharmaceutical Gets DOJ Subpoena for Documents Related to Vimizim, Naglazyme DJ
BioMarin Pharma gets DOJ subpoena on certain drug testing programs RE
Wedbush Adjusts BioMarin Pharmaceutical's PT to $80 From $78, Keeps Neutral Rating; Continues to See Limited Upside MT
Transcript : BioMarin Pharmaceutical Inc., Q4 2023 Earnings Call, Feb 22, 2024
BioMarin Pharmaceutical Q4 Adjusted Earnings, Revenue Rise, 2024 Outlook Set -- Shares Decline After Hours MT
BioMarin Pharmaceutical Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Earnings Flash (BMRN) BIOMARIN PHARMACEUTICAL Posts Q4 EPS $0.49 MT
Earnings Flash (BMRN) BIOMARIN PHARMACEUTICAL Posts Q4 Revenue $646.2M MT
BioMarin Pharmaceutical Inc. Provides Earnings Guidance for the Year 2024 CI
BioMarin Pharmaceutical Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
BofA Securities Cuts BioMarin Pharmaceutical Price Target to $150 From $170, Maintains Buy Rating MT
Biomarin Pharmaceutical Inc. Announces Resignation of Jeffrey Ajer as Executive Vice President and Chief Commercial Officer, Effective from July 1, 2024 CI
Biomarin Pharmaceutical Insider Sold Shares Worth $1,945,700, According to a Recent SEC Filing MT
Transcript : BioMarin Pharmaceutical Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-08-2024 10:30 AM
Biomarin Pharmaceutical Insider Sold Shares Worth $939,900, According to a Recent SEC Filing MT
BioMarin Pharmaceutical Enters into a Cooperation Agreement with Elliott Investment Management CI
Chart BioMarin Pharmaceutical Inc.
More charts
BioMarin Pharmaceutical Inc. (BioMarin) is a biotechnology company, which is engaged in developing and commercializing therapies that address the root cause of genetic conditions. BioMarin's commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa), Aldurazyme (laronidase), Roctavian (valoctocogene roxaparvovec), Kuvan (sapropterin dihydrochloride), and Voxzogo (vosoritide). Vimizim is an enzyme replacement therapy for the treatment of MPS IVA, a lysosomal storage disorder. The Roctavian is an adeno associated virus (AAV5) vector gene therapy designed to restore factor VIII plasma concentrations in patients with severe hemophilia A. Voxzogo is a once daily injection analog of C-type Natriuretic Peptide (CNP) for the treatment of achondroplasia. Brineura is a recombinant human tripeptidyl peptidase 1 (TPP1) for the treatment of patients with CLN2, a form of Batten disease.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
30
Last Close Price
88.61 USD
Average target price
109.8 USD
Spread / Average Target
+23.95%
Consensus